124 related articles for article (PubMed ID: 31082724)
1. Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans.
Khayeka-Wandabwa C; Ma X; Cao X; Nunna V; Pathak JL; Bernhardt R; Cai P; Bureik M
Int Immunopharmacol; 2019 Aug; 73():64-71. PubMed ID: 31082724
[TBL] [Abstract][Full Text] [Related]
2. Concomitant occurence of multiple autoantibodies against human cytochromes P450.
Khayeka-Wandabwa C; Ma X; Jia Y; Bureik M
Int Immunopharmacol; 2021 Nov; 100():108087. PubMed ID: 34464888
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of autoantibodies against CYP4Z1 in patients with colon, ovarian, or prostate cancer.
Khayeka-Wandabwa C; Ma X; Jia Y; Bureik M
Immunobiology; 2022 Mar; 227(2):152174. PubMed ID: 34999392
[TBL] [Abstract][Full Text] [Related]
4. CYP4Z1 - A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer.
Yang X; Hutter M; Goh WWB; Bureik M
Curr Pharm Des; 2017; 23(14):2060-2064. PubMed ID: 28176668
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma.
Rieger MA; Ebner R; Bell DR; Kiessling A; Rohayem J; Schmitz M; Temme A; Rieber EP; Weigle B
Cancer Res; 2004 Apr; 64(7):2357-64. PubMed ID: 15059886
[TBL] [Abstract][Full Text] [Related]
6. Anti-CYP4Z1 autoantibodies detected in breast cancer patients.
Nunna V; Jalal N; Bureik M
Cell Mol Immunol; 2017 Jun; 14(6):572-574. PubMed ID: 28435160
[No Abstract] [Full Text] [Related]
7. 1-Benzylimidazole attenuates the stemness of breast cancer cells through partially targeting CYP4Z1.
Qin H; Zhou Y; Liu H; Yuan Y; Guo Q; Yuan M; Xi T; Zhang Y
Environ Toxicol; 2024 Mar; 39(3):1505-1520. PubMed ID: 37994574
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of estrogen receptor alpha (ERα) expression in transgenic mice expressing human CYP4Z1.
Khayeka-Wandabwa C; Zhao J; Pathak JL; Wu H; Bureik M
Breast Cancer Res Treat; 2022 Jan; 191(2):319-326. PubMed ID: 34725776
[TBL] [Abstract][Full Text] [Related]
9. Efficient substrate screening and inhibitor testing of human CYP4Z1 using permeabilized recombinant fission yeast.
Yan Q; Machalz D; Zöllner A; Sorensen EJ; Wolber G; Bureik M
Biochem Pharmacol; 2017 Dec; 146():174-187. PubMed ID: 28951277
[TBL] [Abstract][Full Text] [Related]
10. CYP4Z1 3'UTR represses migration of human breast cancer cells.
Wang B; Zheng L; Chou J; Li C; Zhang Y; Meng X; Xi T
Biochem Biophys Res Commun; 2016 Sep; 478(2):900-7. PubMed ID: 27520371
[TBL] [Abstract][Full Text] [Related]
11. Serum autoantibodies recognizing 5-hydroxymethyl-2'-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women.
Frenkel K; Karkoszka J; Glassman T; Dubin N; Toniolo P; Taioli E; Mooney LA; Kato I
Cancer Epidemiol Biomarkers Prev; 1998 Jan; 7(1):49-57. PubMed ID: 9456243
[TBL] [Abstract][Full Text] [Related]
12. There and Back Again: A Perspective on 20 Years of CYP4Z1.
Kowalski JP; Rettie AE
Drug Metab Dispos; 2024 May; 52(6):498-507. PubMed ID: 38604728
[TBL] [Abstract][Full Text] [Related]
13. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.
Zheng L; Li X; Meng X; Chou J; Hu J; Zhang F; Zhang Z; Xing Y; Liu Y; Xi T
Mol Cell Endocrinol; 2016 May; 427():133-42. PubMed ID: 26980484
[TBL] [Abstract][Full Text] [Related]
14. The competing endogenous RNA network of CYP4Z1 and pseudogene CYP4Z2P exerts an anti-apoptotic function in breast cancer.
Li C; Zheng L; Xin Y; Tan Z; Zhang Y; Meng X; Wang Z; Xi T
FEBS Lett; 2017 Apr; 591(7):991-1000. PubMed ID: 28236635
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor.
Machalz D; Li H; Du W; Sharma S; Liu S; Bureik M; Wolber G
Eur J Med Chem; 2021 Apr; 215():113255. PubMed ID: 33611185
[TBL] [Abstract][Full Text] [Related]
16. Importance of asparagine-381 and arginine-487 for substrate recognition in CYP4Z1.
Du W; Machalz D; Yan Q; Sorensen EJ; Wolber G; Bureik M
Biochem Pharmacol; 2020 Apr; 174():113850. PubMed ID: 32044355
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer.
Tabuchi Y; Shimoda M; Kagara N; Naoi Y; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2016 May; 157(1):55-63. PubMed ID: 27113738
[TBL] [Abstract][Full Text] [Related]
18. Expression and Functional Characterization of Breast Cancer-Associated Cytochrome P450 4Z1 in
McDonald MG; Ray S; Amorosi CJ; Sitko KA; Kowalski JP; Paco L; Nath A; Gallis B; Totah RA; Dunham MJ; Fowler DM; Rettie AE
Drug Metab Dispos; 2017 Dec; 45(12):1364-1371. PubMed ID: 29018033
[TBL] [Abstract][Full Text] [Related]
19. Plasma Autoantibodies Associated with Basal-like Breast Cancers.
Wang J; Figueroa JD; Wallstrom G; Barker K; Park JG; Demirkan G; Lissowska J; Anderson KS; Qiu J; LaBaer J
Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1332-40. PubMed ID: 26070530
[TBL] [Abstract][Full Text] [Related]
20. Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer.
Friesenhengst A; Pribitzer-Winner T; Miedl H; Pröstling K; Schreiber M
Horm Cancer; 2018 Apr; 9(2):128-138. PubMed ID: 29363090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
